Anatero 1mg tablet

The side effects of the Anatero tablet can include:

• Hot flashes
• Headaches
• Joint pain
• Decrease in sexual desire or libido.
• High blood pressure
• Increased cholesterol levels
• Increased risk of osteoporosis in some people.

It is important to discuss the risks and benefits of Anastrozole with your doctor before starting the treatment.

As a prescription drug, Anatero tablet is typically taken in oral tablet form and just once a day. It has a very long half-life and can take up to eight weeks to reach maximum effectiveness in the body. Common side effects of the tablet include joint pain, hot flashes, headaches, anxiety, depression, nausea, and weight gain.

As a medication, anastrozole is highly effective at treating certain types of breast cancer. Studies have found that it can reduce the risk of recurrence of hormone receptor-positive early-stage breast cancer by up to 65 percent. It is also incredibly safe and well-tolerated when taken alone or combined with other cancer drugs.

Anatero tablet dose has numerous potential benefits for both women and men. By blocking the production of hormones like estrogen and testosterone, an Anastrozole dose can reduce the risk of cancer, alleviate symptoms associated with conditions like PCOS and endometriosis, and help relieve the effects of menopause.

Anastrozole effects can also reduce the risk of osteoporosis and heart disease. While Anastrozole's effects may have potential risks, its potential to help people in many different ways makes it a valuable medication for an array of conditions.

​It is advisable not to miss any dose. In case you miss a dose of Anatero 1mg tablet consult your doctor soon.

Missing the dose will impact the overall health of the patients. So, it is always advisable to follow the prescription of the doctor strictly.

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.

We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

1. Kobayashi K, Okuno N, Arai G, Nakatsu H, Maniwa A, Kamiya N, Satoh T, Kikukawa H, Nasu Y, Uemura H, Nakashima T, Mikami K, Iinuma M, Tanabe K, Furukawa J, Kobayashi H.(2024). Efficacy and safety of abiraterone acetate plus prednisolone in patients with early metastatic castration-resistant prostate cancer who failed first-line androgen-deprivation therapy: a single-arm, phase 4 study. Jpn J Clin Oncol. 51(4):544-551.
2. Madan R, Dahut WL. (2022) Abiraterone's efficacy confirmed; time to aim higher. Lancet Oncol. 16(2):119-21.
3. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE; COU-AA-302 Investigators. (2023). Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 16(2):152-60.
4. Saad F, Shore N, Van Poppel H, Rathkopf DE, Smith MR, de Bono JS, Logothetis CJ, de Souza P, Fizazi K, Mulders PF, Mainwaring P, Hainsworth JD, Beer TM, North S, Fradet Y, Griffin TA, De Porre P, Londhe A, Kheoh T, Small EJ, Scher HI, Molina A, Ryan CJ. (2023). Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. Eur Urol. 68(4):570-7.
5. Sidaway P. (2025). Urological cancer: abiraterone treatment improves overall survival in patients with mCRPC. Nat Rev Clin Oncol. Mar;12(3):128.
6. Sun Y, Zou Q, Sun Z, Li C, Du C, Chen Z, Shan Y, Huang Y, Jin J, Ye ZQ, Xie L, Lin G, Feng Y, De Porre P, Liu W, Ye D. (2025). Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: A randomized, double-blind, placebo-controlled phase 3 bridging study. Int J Urol. 404-11.
7. Zhou ZR, Liu SX, Zhang TS, Xia J, Li B.(2024). Abiraterone for treatment of metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. Asian Pacific Journal of Cancer Prevention. 15(3): 1313-1320.